What Happened to Triple H Therapy?
Triple H Therapy used to be commonly utilized to prevent vasospasm in patients with subarachnoid hemorrhage. The H’s stand for hypertension, hypervolemia, and hemodilution. The evidence has shown that this treatment modality is associated with increased complications, namely pulmonary edema and resulting hypoxia. Current management for vasospasm prevention includes:
- Nimodipine, a dihydropyridine calcium channel blocker that acts as a vasodilator is administered four times a day for 21 days
- Maintenance of euvolemia
- Induced hypertension
- Endovascular therapy, which involves insertion of a catheter into the narrowed artery to delivery medication or inflate a balloon. This treatment is used to treat symptomatic vasospasm that has not responded to medical therapy.
References
____________________________________________________________
The information, including but not limited to, audio, video, text, and graphics contained on this website are for educational purposes only. No content on this website is intended to guide nursing practice and does not supersede any individual healthcare provider’s scope of practice or any nursing school curriculum. Additionally, no content on this website is intended to be a substitute for professional medical advice, diagnosis or treatment.
Last Updated on January 27, 2025 by Maureen Osuna, MSN, RN
